Therapeutic Strategies for Targeting CDKN2A Loss in Melanoma

Loss of the tumor suppressor gene CDKN2A, encoding p16 and p14, is a frequent event driving melanoma progression. Therefore, therapeutic strategies aimed at CDKN2A loss hold great potential to improve melanoma treatment. Pharmacological inhibition of the p16 targets CDK4/6 is a prime example of such...

Full description

Saved in:
Bibliographic Details
Published inJournal of investigative dermatology Vol. 143; no. 1; pp. 18 - 25.e1
Main Authors Kreuger, Inger Z.M., Slieker, Roderick C., van Groningen, Tim, van Doorn, Remco
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.01.2023
Subjects
Cyclin-Dependent Kinase Inhibitor p16 - genetics
Genes, p16
Humans
Melanoma - drug therapy
Melanoma - genetics
SASP
ICI
MTA
Online AccessGet full text

Cover

More Information
Summary:Loss of the tumor suppressor gene CDKN2A, encoding p16 and p14, is a frequent event driving melanoma progression. Therefore, therapeutic strategies aimed at CDKN2A loss hold great potential to improve melanoma treatment. Pharmacological inhibition of the p16 targets CDK4/6 is a prime example of such a strategy. Other approaches exploit cell cycle deregulation, target metabolic rewiring, epigenetically restore expression, act on dependencies resulting from co-deleted genes, or are directed at the effects of CDKN2A loss on immune responses. This review explores these therapeutic strategies targeting CDKN2A loss, which potentially open up new avenues for precision medicine in melanoma.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0022-202X
1523-1747
1523-1747
DOI:10.1016/j.jid.2022.07.016